Ocugen (OCGN) Investor Presentation - Slideshow

COVAXIN™ (BBV152) COVID-19 Vaccine - COVAXIN™ is a whole-virion inactivated SARS-CoV-2 vaccine candidate licensed from Bharat Biotech for the US and Canadian markets[11] - Phase 3 data suggests 77.8% overall efficacy[17] - Phase 3 data suggests 93.4% efficacy against severe COVID-19 disease[17] - Phase 3 data suggests 65.2% efficacy against the Delta variant (B16172)[17] - The vaccine is designed for broad spectrum immune response, generating both humoral and cellular responses against multiple viral proteins[15] - The vaccine has a strong safety profile in adult and pediatric populations, and can be stored and shipped at 2°-8°C with a 2-year shelf life and 6-month stability at room temperature[16] - A Phase 2/3 immuno-bridging and broadening study (OCU-002) is planned, with an estimated enrollment of 400 participants[19] OCU400 Modifier Gene Therapy Platform - OCU400 is a modifier gene therapy platform designed to address many rare diseases as well as complex diseases that affect millions[24] - A Phase 1/2 study is underway to assess the safety and efficacy of OCU400 for retinitis pigmentosa associated with NR2E3 and RHO mutations, with an estimated enrollment of 18 participants[30] - Preclinical study suggests potency of modifier gene therapy to elicit broad-spectrum therapeutic benefits in early and advanced stages of RP[28]